Abstract As of May 1, 2017, 74 antibody-based molecules have been approved by a
regulatory authority in a major market. Additionally, there are 70 and 575 antibody-based …

Engineered antibodies now represent over 30% of biopharmaceuticals in clinical trials, as
highlighted by recent approvals from the US Food and Drug Administration. Recombinant …

The emergence of recombinant technologies has revolutionized the selection and
production of monoclonal antibodies, allowing the design of fully human antibodies of any …

More than a century after the first Nobel Prize was awarded for an antibody-based therapy,
these molecules continue to fascinate researchers and inspire novel therapeutic …

With more than 20 molecules in clinical use, monoclonal antibodies have finally come of age
as therapeutics, generating a market value of 11billionin2004,expectedtoreach 26 billion by …

Since the first monoclonal antibody drug, muromonab-CD3, was approved for marketing in
1986, 165 antibody drugs have been approved or are under regulatory review worldwide …

Therapeutic antibodies represent one of the fastest growing areas of the pharmaceutical
industry. There are currently 18 monoclonal antibodies in the market that have been …

It has been over four decades since the development of monoclonal antibodies (mAbs)
using a hybridoma cell line was first reported. Since then more than thirty therapeutic …

Antibodies are essential in modern life sciences biotechnology. Their architecture and
diversity allow for high specificity and affinity to a wide array of biochemicals. Combining …

Proteins have sparked fast growing interest as biological therapeutic agents for several
diseases. Antibodies, in particular, carry an enormous potential as drugs owing to their …